11 - 20 (out of 21)
CAR inhibitors for the treatment of heart attack
The Coxsackievirus and Adenovirus Receptor (CAR) is a cell contact protein that mediates virus uptake and is essential for early heart development. Mice lacking CAR are protected against Coxsackievirus infection and show hardly any health restrictions.
| Principal Investigators | Michael Gotthardt (Max Delbrück Center for Molecular Medicine in the Helmholtz Association) |
|---|---|
| Project status | running |
Detection of plaque vulnerability with a novel hybrid intravascular NIRF-IVUS imaging system
Atherosclerosis is a chronic inflammation of the vessel wall. Unstable atherosclerotic plaques can rupture and pose a risk of cardiovascular events such as heart attack or stroke.
| Principal Investigators | Michael Joner (German Heart Centre Munich) |
|---|---|
| Project status | running |
A novel inotropic/lusitropic peptide drug against decompensated chronic heart failure
The objectives of this proposal are the preclinical development of a cardiac-targeted peptide drug with inotropic and lusitropic effects for the short-term intravenous treatment of decompensated chronic heart failure (CHF) and its clinical translation into a first-in-human clinical trial. The life-threatening complication of the clinical syndrome presents a significant unmet medical need given its high mortality and severe adverse effects of clinical drugs to reconstitute cardiac performance.
| Principal Investigators | Patrick Most, Hugo Katus (University Hospital Heidelberg) |
|---|---|
| Project status | completed |
Low-energy defibrillation of ventricular fibrillati-on in pigs as an animal model for heart failure
In previous studies run by the working group led by Stefan Luther it was shown that the energy applied in cardiac arrhythmias could be reduced by 80 to 90 percent compared to conventional defibrillations.
| Principal Investigators | Stefan Luther, Gerd Hasenfuß (Max Planck Institute for Dynamics and Self-Organisation, University Medical Centre Göttingen) |
|---|---|
| Project status | completed |
Development of miR-92a inhibitors for the treatment of cardiovascular diseases
Based on own preliminary works that show that miR-92a inhibitors can improve cardiac function after infarction, the safety and optimisation studies necessary for an application in human beings are to be carried out in the context of the application.
| Principal Investigators | Stefanie Dimmeler (Goethe University Frankfurt) |
|---|---|
| Project status | completed |
IPSC-EHT transplantation for cardiac repair – towards first-in-patient
The mortality rate of patients with end-stage heart failure is high, while treatment options are very limited. The availability of cardiomyocytes, which are obtained from induced pluripotent stem cells, makes it possible to culture artificial heart muscles, which can be used in allogenic transplantation.
| Principal Investigators | Thomas Eschenhagen, Arne Hansen (University Hospital Hamburg-Eppendorf) |
|---|---|
| Project status | completed |
GMP-production of engineered human myocardium for heart failure repair
Irreversible and progressive loss of cardiomyocytes is the underlying cause of heart failure. Remuscularization of the failing heart can be achieved by epicardial implantation of tissue engineered myocardium.
| Principal Investigators | Wolfram H. Zimmermann (University Medical Centre Göttingen) |
|---|---|
| Project status | completed |
Gene Therapy of Cardiac Hypertrophy
The project wants to test a novel therapeutic approach in a pig model of acquired cardiac hypertrophy using inhibition of the transcription factor NFAT, which has been shown to control the hypertrophic gene programme in aortic stenosis but also hereditary forms of cardiac hypertrophy.
| Principal Investigators | Oliver Müller |
|---|---|
| Project status | running |
Development and characterization of a pig model of TET2-mediated clonal hematopoiesis
Clonal haematopoiesis is a risk factor for cardiovascular disease. To better understand the underlying mechanisms, the project will develop a large animal model.
| Principal Investigators | Christian Schulz (University Hospital of Munich) |
|---|---|
| Project status | running |
CardioXeno Clinical Translation of Cardiac Xenotransplantation
Die Xenotransplantation genetisch angepasster Schweineherzen könnte eine Lösung für den akuten Mangel an Spenderorganen in Deutschland bieten.
| Principal Investigators | Christian Hagl, Klinikum der Universität München |
|---|---|
| Project status |